Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Eli Lilly wins FDA nod for COVID-19 antibody treatment

By Brian Buntz | November 10, 2020

The FDA issued an emergency use authorization (EUA) yesterday for the investigational monoclonal antibody therapy bamlanivimab (LY-CoV555) to treat COVID-19.

The drug from Eli Lilly (NYSE:LLY) is intended to reduce the risk of severe COVID-19 infections when administered within 10 days of developing symptoms.

The manufacturer indicates the drug for mild-to-moderate COVID-19 infections in adult and pediatric patients 12 years old or older weighing at least 88 pounds. People who are over 65 and obese could potentially benefit most from the drug, according to the FDA.

“[T]he FDA remains committed to expediting the development and availability of potential COVID-19 treatments and providing sick patients timely access to new therapies where appropriate, while at the same time supporting research to further evaluate whether they are safe and effective,” said FDA Commissioner Dr. Stephen M. Hahn in a statement.

Preliminary trial data indicate that bamlanivimab reduces COVID-19-related hospitalization or emergency room visits in high-risk patients compared to a placebo, the agency noted. Bamlanivimab was designed to target the spike protein of the novel coronavirus, potentially blocking the virus’ entry into human cells.

Former New Jersey governor Chris Christie received the drug when he was infected with COVID-19, according to the New York Times.

HHS plans to allocate 300,000 doses of bamlanivimab immediately, according to an announcement from the health department. HHS and the Department of Defense had agreed to pay $375 million to buy 300,000 doses of the drug to add to a stockpile.

The FDA has not indicated the drug for hospitalized COVID-19 patients and suggested that monoclonal antibodies like bamlanivimab may worsen clinical outcomes for hospitalized patients requiring oxygen or mechanical ventilation.

Eli Lilly has also filed for an EUA to use Olumiant (baricitinib), a rheumatoid arthritis treatment, to hasten COVID-19 recovery time.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 antibody treatment, Eli Lilly & Co., FDA, U.S. Department of Defense, U.S. Department of Health & Human Services
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50